Get the Stockscreener App
0.7877
3.26%
0.0249
After Hours:
.78
-0.0077
-0.98%
Xilio Therapeutics Inc stock is traded at $0.7877, with a volume of 61,558.
It is up +3.26% in the last 24 hours and down -8.18% over the past month.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).
See More
Previous Close:
$0.7628
Open:
$0.7595
24h Volume:
61,558
Relative Volume:
0.44
Market Cap:
$33.89M
Revenue:
-
Net Income/Loss:
$-81.22M
P/E Ratio:
-0.2566
EPS:
-3.07
Net Cash Flow:
$-74.41M
1W Performance:
+4.22%
1M Performance:
-8.18%
6M Performance:
-27.06%
1Y Performance:
-62.67%
1-Day Range:
$0.7464
$0.791
1-Week Range:
$0.7218
$0.8084
52-Week Range:
$0.49
$2.8938
Xilio Therapeutics Inc Stock (XLO) Company Profile
Name
Xilio Therapeutics Inc
Sector
Industry
Phone
617-833-1027
Address
828 WINTER STREET, WALTHAM
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-21-22 | Initiated | Chardan Capital Markets | Buy |
| Jan-10-22 | Initiated | H.C. Wainwright | Buy |
| Nov-16-21 | Initiated | Cowen | Outperform |
| Nov-16-21 | Initiated | Guggenheim | Buy |
| Nov-16-21 | Initiated | Morgan Stanley | Overweight |
| Nov-16-21 | Initiated | Raymond James | Outperform |
View All
Xilio Therapeutics Inc Stock (XLO) Latest News
XOS stock touches 52-week low at $4.62 amid market challenges - Investing.com
XBP stock plunges to 52-week low at $1.05 amid market challenges - Investing.com
XPEV: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
Xilio Therapeutics Inc (XLO) rating initates by Chardan Capital Markets - Knox Daily
Market Resilience: XTI Aerospace Inc. (XTIA) Finishes Weak at 0.22, Down -4.06 - The Dwinnex
Tencent-Backed AI Drug Researcher Xtalpi’s Shares Double On Revenue Rise - Forbes Africa
Xilio Therapeutics Inc (XLO)’s highs and lows: A closer look at its stock price fluctuations - US Post News
(XFLT) Trading Signals - Stock Traders Daily
Balance Sheet Breakdown: Xilio Therapeutics Inc (XLO)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
There’s evidence fragile X symptoms can be reduced with an experimental drug - KUOW News and Information
Slew of New Drugs Sends Xencor Shares Soaring - Los Angeles Business Journal
XBiotech (NASDAQ:XBIT) Shares Pass Above 50 Day Moving Average of $6.63 - Defense World
XTX Topco Ltd Has $2.01 Million Stock Position in IQVIA Holdings Inc. (NYSE:IQV) - Defense World
Xilio Therapeutics faces Nasdaq delisting over share price - Investing.com India
Xilio Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Australia
Xilio Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com UK
Xilio Therapeutics faces Nasdaq delisting over share price - Investing.com
XLO Stock Sees Decline of Approximately -10.26% in Last Five Days - Knox Daily
Analytical Lens: Exploring Xilio Therapeutics Inc (XLO)’s Financial Story Through Ratios - The Dwinnex
Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference - GlobeNewswire
Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference - StockTitan
Xilio Therapeutics shares hold Buy rating on clinical trial focus - Investing.com
Xilio Therapeutics shares hold Buy rating on clinical trial focus By Investing.com - Investing.com Canada
Xilio Therapeutics shares hold Buy rating on clinical trial focus By Investing.com - Investing.com UK
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results - GlobeNewswire
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results - Yahoo Finance
Understanding the Risks of Investing in Xilio Therapeutics Inc (XLO) - Knox Daily
Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Update - Defense World
Here's Why We're A Bit Worried About Xilio Therapeutics' (NASDAQ:XLO) Cash Burn Situation - Simply Wall St
Head to Head Analysis: Indivior (NASDAQ:INDV) versus Xilio Therapeutics (NASDAQ:XLO) - Defense World
Can Xilio Therapeutics (NASDAQ:XLO) Afford To Invest In Growth? - Yahoo Finance
Short Interest in Xilio Therapeutics, Inc. (NASDAQ:XLO) Drops By 83.1% - Defense World
Head to Head Analysis: Xilio Therapeutics (NASDAQ:XLO) versus VBI Vaccines (NASDAQ:VBIV) - Defense World
Biopharma Layoff Tracker 2024: Ginkgo, Cara, Barinthus and More Cut Staff - BioSpace
Xilio Therapeutics Inc (XLO) stock analysis: A comprehensive overview – US Post News - US Post News
Investing in Xilio Therapeutics Inc (XLO): What You Must Know – Knox Daily - Knox Daily
Xilio Therapeutics Inc (XLO)'s Market Momentum: Closing Strong at 0.95, Down -0.33 – DWinneX - The Dwinnex
Xilio Therapeutics, Inc. (NASDAQ:XLO) Shares Sold by Octagon Capital Advisors LP - Defense World
Xilio Therapeutics expands board with industry experts - Investing.com India
Xilio Therapeutics expands board with industry experts By Investing.com - Investing.com
Xilio Therapeutics Enhances Board with Two New DirectorsTipRanks.com - TipRanks
Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors - ForexTV.com
Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors - GlobeNewswire
Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors - Yahoo Finance
Was there any good news for Xilio Therapeutics Inc (XLO) stock in the last session? – US Post News - US Post News
Monitoring Xilio Therapeutics Inc (XLO) after recent insider movements – Knox Daily - Knox Daily
Xilio Therapeutics (NASDAQ:XLO) Trading Down 2.8% - Defense World
Xilio Therapeutics Inc (XLO) Stock: A Year of Decreases and Increases - The InvestChronicle
Gilead and Cartography enter deal to develop cancer therapies - Yahoo Finance
Market Recap: Xilio Therapeutics Inc (XLO)'s Negative Momentum, Closing at 1.05 – DWinneX - The Dwinnex
Contrasting Xilio Therapeutics (NASDAQ:XLO) & NLS Pharmaceutics (NASDAQ:NLSP) - Defense World
Xilio Therapeutics Inc Stock (XLO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):